• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Oncopeptides treatment for multiple myeloma

March 1, 2021 By Sean Whooley

OncopeptidesOncopeptides (STO:ONCO) announced today that it received FDA approval for its Pepaxto treatment for multiple myeloma.

Waltham, Mass.-based Oncopeptides’ Pepaxto (melphalan flufenamide) received approval in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one CD38-directed monoclonal antibody, according to a news release.

The company touts Pepaxto, which was approved based on results from its Horizon trial, as the first anticancer peptide-drug conjugate approved for multiple myeloma.

Pepaxto uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound that helps to deliver Papxto into cells to leverage aminopeptidases that are overexpressed in multiple myeloma cells and cause the release of the cytotoxic agents. It is administered once per month in a 30-minute infusion process.

The Horizon trial evaluated 157 patients with relapsed or refractory multiple myeloma, with 97 of the patients falling under the triple-class refractory category with at least four prior lines of treatment. The overall response rate for that group was 23.7% and the median duration of response was more than four months.

Oncopeptides expects the Pepaxto treatment to be made commercially available in the U.S. within approximately two weeks.

“We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma,” Oncopeptides chief scientific officer Jakob Lindberg said in the news release. “Pepaxto uses innovative technology that links a peptide carrier to a cytotoxic agent. The conjugated agent is a highly lipophilic compound, which allows it to be rapidly distributed into cells. The compound then leverages aminopeptidases that are overexpressed in multiple myeloma cells, causing the release of the cytotoxic payload.”

Pepaxto received FDA approval under an accelerated timeline based on the results of the Horizon trial.

“The accelerated U.S. approval of Pepaxto is a key step forward in fulfilling Oncopeptides’ core mission, to bring hope to patients in their battle against difficult-to-treat hematological diseases,” CEO Marty Duvall added. “Moving ahead, our focus is to further advance Pepaxto. We look forward to receiving top-line data from the phase 3 OCEAN study in the second quarter. This comparative study is designed to support a future supplementary New Drug Application to expand the label.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance Tagged With: FDA, Oncopeptides

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS